The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab

Vaccine

Volumn 29, Issue 8, 2011, Pages 1643-1648

  Arad, U ^a   Tzadok, S ^a   Amir, S ^a   Mandelboim, M ^b   Mendelson, E ^b   Wigler, I ^a   Sarbagil Maman, H ^a   Paran, D ^a   Caspi, D ^a   Elkayam, O ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Cellular immunity; Immunization; Influenza; Rheumatoid arthritis; Rituximab

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLUENZA VACCINE; METHOTREXATE; PREDNISONE; RITUXIMAB;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; B CELL DEPLETION; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL SELECTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; VACCINATION REACTION;

EID: 79952693877     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.072     Document Type: Article

References (31)

1. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
2. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
3. Bongartz T,Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V.Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
4. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39:327-46.
5. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908.
6. van Vollenhoven RF, Emery P, Bingham 3rd CO, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558-67.
7. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory CommitteeonImmunization Practices (ACIP),2009. MMWR Recomm Rep 2009;58:1-52.
8. Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994;21:1203-6.
9. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006;65:191-4.
10. Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol 2010;134:113-20.
11. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop 2009;49:9-13.
12. Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008;67:937-41.
13. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62:75-81.
14. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006;12:48-54.
15. Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montano LF, Nichol KL, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009;27:5043-53.
16. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006;176:6333-9.
17. Holvast A, de Haan A, van Assen S, Stegeman CA, Huitema MG, Huckriede A, et al. Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis. Ann Rheum Dis 2010;69:924-7.
18. Topham DJ, Tripp RA, Hamilton-Easton AM, Sarawar SR, Doherty PC. Quantitative analysis of the influenza virus-specific CD4+ T cell memory in the absence of B cells and Ig. J Immunol 1996;157:2947-52.
19. Epstein SL, Lo CY, Misplon JA, Bennink JR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 1998;160:322-7.
20. Whitmire JK, Asano MS, Kaech SM, Sarkar S, Hannum LG, Shlomchik MJ, et al. Requirement of B cells for generating CD4+ T cell memory. J Immunol 2009;182:1868-76.
21. Shen H, Whitmire JK, Fan X, Shedlock DJ, Kaech SM, Ahmed R. A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes. J Immunol 2003;170:1443-51.
22. Bouaziz JD,YanabaK,Venturi GM, WangY,Tisch RM, Poe JC,etal. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 2007;104:20878-83.
23. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983;309:13-7.
24. Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008;15:1042-53.
25. McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, et al. Granzyme B: correlates with protection and enhanced CTL responseto influenza vaccination in older adults. Vaccine 2009;27:2418-25.
26. Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell responses toinfluenza: reduced activation ex vivo, decreased expansion inCTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 2004;172:3437-46.
27. Lindemann M, Witzke O, Lutkes P, Fiedler M, Kreuzfelder E, Philipp T, et al. ELISpot assayasasensitive tooltodetect cellular immunity following influenza vaccination in kidney transplant recipients. Clin Immunol 2006;120:342-8.
28. Madan RP, Tan M, Fernandez-Sesma A, Moran TM, Emre S, Campbell A, et al. A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings. Clin Infect Dis 2008;46:712-8.
29. Avetisyan G, Ragnavolgyi E, Toth GT, Hassan M, Ljungman P. Cellmediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients. Bone Marrow Transplant 2005;36:411-5.
30. Holvast A,van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, etal.Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum 2009;60:2438-47.
31. Setti M, Fenoglio D, Ansaldi F, Filaci G, Bacilieri S, Sticchi L, et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009;27:3367-72.